Specifically, in a mouse model of metastatic RCC, a synergistic anti-tumor response with the combined treatment of sunitinib and an agonistic mAb against the glucocorticoid-induced TNFR related protein (GITR) was shown [168]. The gene discussed is TNFRSF18; the disease is neoplasm.